Etoposide Selectively Ablates Activated T Cells To Control the Immunoregulatory Disorder Hemophagocytic Lymphohistiocytosis

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Journal of Immunology

• Publication date

  2014-01-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.4049/jimmunol.1302282PMID 24259502PMCID PMC4177106
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Eliminating Encephalitogenic T Cells without Undermining Protective Immunity

  2014cited by this paper
• Perforin deficiency impairs a critical immunoregulatory loop involving murine CD8(+) T cells and dendritic cells.

  2013influential reference
• Contemporary diagnostic methods for hemophagocytic lymphohistiocytic disorders.

  2011cited by this paper
• How I treat hemophagocytic lymphohistiocytosis.

  2011cited by this paper
• Hemophagocytosis causes a consumptive anemia of inflammation

  2011cited by this paper
• Perforin is a critical physiologic regulator of T-cell activation.

  2011cited by this paper
• Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol.

  2011cited by this paper
• High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease.

  2010cited by this paper
• Familial hemophagocytic lymphohistiocytosis

  2010cited by this paper
• Consecutive low doses of cyclophosphamide preferentially target Tregs and potentiate T cell responses induced by DNA PLG microparticle immunization.

  2010cited by this paper
• Moderate increase in Mdr1a/1b expression causes in vivo resistance to doxorubicin in a mouse model for hereditary breast cancer.

  2009cited by this paper
• Enhancement of the in vivo antitumor activity of clofarabine by 1-β-d-[4-thio-arabinofuranosyl]-cytosine

  2009cited by this paper
• Treatment Outcomes with CHOP Chemotherapy in Adult Patients with Hemophagocytic Lymphohistiocytosis

  2008cited by this paper
• Treatment with anti‐CC chemokine receptor 3 monoclonal antibody or dexamethasone inhibits the migration and differentiation of bone marrow CD34+ progenitor cells in an allergic mouse model

  2008cited by this paper
• Milk fat globule-EGF factor 8/lactadherin plays a crucial role in maintenance and repair of murine intestinal epithelium.

  2007cited by this paper
• HLH‐2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis

  2007cited by this paper
• Dose translation from animal to human studies revisited

  2007cited by this paper
• Hemophagocytic syndromes.

  2007cited by this paper
• Etoposide‐related secondary acute myeloid leukemia (t‐AML) in hemophagocytic lymphohistiocytosis

  2007cited by this paper
• 5-Fluorouracil dose escalation enabled with PN401 (triacetyluridine): toxicity reduction and increased antitumor activity in mice

  2006cited by this paper
• The Cancer Chemotherapy Drug Etoposide (VP-16) Induces Proinflammatory Cytokine Production and Sickness Behavior–like Symptoms in a Mouse Model of Cancer Chemotherapy–Related Symptoms

  2006cited by this paper
• Cisplatin Inactivation of Caspases Inhibits Death Ligand-induced Cell Death in Vitro and Fulminant Liver Damage in Mice*

  2005cited by this paper
• THE DISTRIBUTION, METABOLISM, AND ELIMINATION OF CLOFARABINE IN RATS

  2005cited by this paper
• Toxicity of the topoisomerase I inhibitors

  2005cited by this paper
• Toxicity of the topoisomerase II inhibitors

  2005cited by this paper
• Targeting cyclooxygenase-2 reduces overt toxicity toward low-dose vinblastine and extends survival of juvenile mice with Friend disease.

  2005cited by this paper
• Pharmacokinetics of VP16-213 in Lewis lung carcinoma bearing mice

  2004cited by this paper
• An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder.

  2004influential reference
• Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation.

  2002cited by this paper
• Enhancement of leukemia rejection by mice successfully treated for L1210 leukemia due to low dose compared to high dose VP-16.

  2002cited by this paper
• Migration and differentiation of CD8+ T cells

  2002cited by this paper
• Activation of apoptosis pathways in peripheral blood lymphocytes by in vivo chemotherapy.

  2001cited by this paper
• The topoisomerase inhibitors camptothecin and etoposide induce a CD95-independent apoptosis of activated peripheral lymphocytes

  2000cited by this paper
• Ionizing Radiation and Chemotherapeutic Drugs Induce Apoptosis in Lymphocytes in the Absence of FAS or Fadd/Mort1 Signaling

  2000cited by this paper
• Ionizing Radiation and Chemotherapeutic Drugs Induce Apoptosis in Lymphocytes in the Absence of FAS or Fadd/Mort1 Signaling Implications for Cancer Therapy

  2000cited by this paper
• Novel approaches to therapy for systemic lupus erythematosus.

  2000cited by this paper
• Induction of apoptosis and caspase activation in cells obtained from familial haemophagocytic lymphohistiocytosis patients

  1999cited by this paper
• High dose versus low dose fludarabine in the treatment of patients with severe refractory rheumatoid arthritis.

  1998cited by this paper
• Detection of antigen-specific T cells with multivalent soluble class II MHC covalent peptide complexes.

  1998cited by this paper
• [Hemophagocytic syndromes].

  1998cited by this paper
• Etoposide: four decades of development of a topoisomerase II inhibitor.

  1998cited by this paper
• implications for cancer therapy

  1996cited by this paper
• Methotrexate resistance in an in vivo mouse tumor due to a non-active-site dihydrofolate reductase mutation.

  1993cited by this paper
• Metabolism and action of purine nucleoside analogs.

  1991cited by this paper
• Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate.

  1988cited by this paper
• Treatment of four patients with erythrophagocytic lymphohistiocytosis by a combination of epipodophyllotoxin, steroids, intrathecal methotrexate, and cranial irradiation.

  1985cited by this paper
• Selection of genetic variants of lymphocytic choriomeningitis virus in spleens of persistently infected mice. Role in suppression of cytotoxic T lymphocyte response and viral persistence

  1984cited by this paper
• Familial hemophagocytic lymphohistiocytosis

  1983cited by this paper
• Successful treatment of lymphohistiocytic reticulosis with phagocytosis with epipodophyllotoxin VP 16–213

  1980cited by this paper
• Familial haemophagocytic reticulosis.

  1968cited by this paper
• Familial Haemophagocytic Reticulosis

  1952cited by this paper

• Cytokine storm

  2026cites this paper
• Development of an early mortality risk prediction model for pediatric patients with secondary hemophagocytic lymphohistiocytosis

  2025cites this paper
• Severe Dengue Associated With Hemophagocytic Lymphohistiocytosis (HLH) in an Adult ICU

  2025cites this paper
• Treating and triggering hyperinflammation: tackling hemophagocytic lymphohistiocytosis and HLH-like syndromes in the pediatric cell therapy and critical care setting

  2025cites this paper
• Immune Effector Cell-associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS).

  2025cites this paper
• Assessing the effectiveness of etoposide treatment in adult haemophagocytic lymphohistiocytosis: a systematic review and meta-analysis

  2025cites this paper
• Hemophagocytic lymphohistiocytosis: do we have a solution for TMI (too much inflammation)?

  2025cites this paper
• Вторичный гемофагоцитарный синдром и хроническая активная болезнь, ассоциированные с вирусом Эпштейна—Барр (обзор литературы)

  2025cites this paper
• Computational microbiome pharmacology analysis elucidates the anti-cancer potential of vaginal microbes and metabolites

  2025cites this paper
• Wolcott-Rallison Syndrome - crosstalk between PERK- EIF2A and type II interferon signaling.

  2025cites this paper
• Hemophagocytic Lymphohistiocytosis.

  2025cites this paper
• T-ing up the storm: pathogenic cycling lymphocytes in the biology of macrophage activation syndrome

  2025cites this paper
• First-line treatment of extensive-stage small cell lung cancer with immune checkpoint inhibitors acting on different targets: a systematic review and network meta-analysis

  2025cites this paper
• Perforin Expression and Natural Killer-Cell Proportion as Biomarkers in Secondary Hemophagocytic Lymphohistiocytosis

  2025cites this paper
• Hemophagocytic Lymphohistiocytosis Secondary To Dengue: A Case Report

  2025cites this paper
• Mechanisms and management of CAR T toxicity

  2024cites this paper
• Network-based Multi-omics Disease–Drug Associations Reveal Drug Repurposing Candidates for Covid-19 Disease Phases

  2024cites this paper
• The effectiveness of the doxorubicin-etoposide-methylprednisolone regimen for adult HLH secondary to rheumatic disease

  2024cites this paper
• Hemophagocytic lymphohistiocytosis post chimeric antigen receptor T cell therapies

  2024cites this paper
• Navigating Complexity: A Case Study on Hemophagocytic Lymphohistiocytosis Diagnosis and Management Challenges

  2024cites this paper
• Successful management of infection and macrophage activation syndrome patient using low-dose etoposide: A case report

  2024cites this paper
• Hemophagocytic lymphohistiocytosis caused by multiple infections during primary chemotherapy for pediatric acute lymphoblastic leukemia: a case report

  2024cites this paper
• Study design and rationale for IFCT- 2203 TAXIO: A study that aims to evaluate the effectiveness of a first-line chemotherapy regimen without etoposide, combined with durvalumab, for patients with extensive disease small cell lung cancer.

  2024cites this paper
• Self‐Assembly of Biocompatible Core‐Shell Nanocapsules with Tunable Surface Functionality by Microfluidics for Enhanced Drug Delivery

  2024cites this paper
• Differential Effects of JAK1 vs. JAK2 Inhibition in Mouse Models of Hemophagocytic Lymphohistiocytosis.

  2024cites this paper
• Progress in Diagnosis and Treatment of Lymphoma-Associated Hemophagocytic Syndrome

  2024cites this paper
• Ruxolitinib-loaded cytokine nanosponge alleviated the cytokine storm and dampened macrophage overactivation for the treatment of hemophagocytic lymphohistiocytosis.

  2024cites this paper
• Etoposide Therapy of Cytokine Storm Syndromes.

  2024cites this paper
• Prevalence and mortality of haemophagocytic lymphohistiocytosis in dengue fever: a systematic review and meta-analysis.

  2024cites this paper
• Hemophagocytic Lymphohistiocytosis in the Context of Hematological Malignancies and Solid Tumors.

  2024cites this paper
• CD8+ T Cell Biology in Cytokine Storm Syndromes.

  2024cites this paper
• Importance of immunosuppression in haemophagocytic lymphohistiocytosis caused by miliary tuberculosis

  2024cites this paper
• EB Virus-Associated Hemophilic Syndrome: A Case Report and Literature Review

  2024cites this paper
• History of Hemophagocytic Lymphohistiocytosis.

  2024cites this paper
• Immunopathology of and potential therapeutics for secondary hemophagocytic lymphohistiocytosis/macrophage activation syndrome: a translational perspective

  2024cites this paper
• PD-1 Blockade-Induced Hemophagocytic Lymphohistiocytosis, a Dilemma Therapeutic Outcome in 2 Patients with CAEBV: A Case Series

  2024cites this paper
• Macrophage Activation Syndrome

  2024cites this paper
• Systemic Epstein-Barr Virus-Positive T-Cell Lymphoma of Childhood Associated With t(1;22)(p22;q11.2) Mutation

  2024cites this paper
• Hemophagocytic lymphohistiocytosis: current treatment advances, emerging targeted therapy and underlying mechanisms

  2024cites this paper
• Not So BenignHemophagocytic Lymphohistiocytosis: A Rare Yet Clinically Significant Syndrome

  2024cites this paper
• Murine Models of Familial Cytokine Storm Syndromes.

  2024cites this paper
• Riding the storm: managing cytokine-related toxicities in CAR-T cell therapy

  2024cites this paper
• Complementary HLH susceptibility factors converge on CD8 T-cell hyperactivation

  2023cites this paper
• A brief overview of SARS-CoV-2 infection and its management strategies: a recent update

  2023cites this paper
• Bojungikgi-tang improves skin barrier function and immune response in atopic dermatitis mice fed a low aryl hydrocarbon receptor ligand diet

  2023cites this paper
• Medium-dose etoposide, cyclophosphamide and total body irradiation conditioning potentiates anti-leukemia immunity in adults with acute lymphoblastic leukemia without aggravating graft-versus-host disease.

  2023cites this paper
• Secondary hemophagocytic lymphohistiocytosis in children (Review)

  2023cites this paper
• Ruxolitinib-based regimen in children with primary hemophagocytic lymphohistiocytosis

  2023cites this paper
• Teclistamab for Multiple Myeloma: Clinical Insights and Practical Considerations for a First-in-Class Bispecific Antibody

  2023cites this paper
• Safety of CAR-T Cell Therapy in Patients With Renal Failure/Acute Kidney Injury: Focused Review

  2023cites this paper
• The Liver in Hemophagocytic Lymphohistiocytosis: Not an Innocent Bystander

  2023cites this paper
• Diagnosis and Management of Adult Malignancy-Associated Hemophagocytic Lymphohistiocytosis

  2023cites this paper
• A prospective, single-center, randomized phase 2 trial of etoposide in severe COVID-19

  2023influential citation
• Cellular and transcriptional impacts of Janus kinase and/or IFN-gamma inhibition in a mouse model of primary hemophagocytic lymphohistiocytosis

  2023cites this paper
• Podophyllotoxin: Recent Advances in the Development of Hybridization Strategies to Enhance Its Antitumoral Profile

  2023cites this paper
• Immune Effector Cell associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS).

  2023cites this paper
• Anakinra versus etoposide‐based therapy added to high‐dose steroids for the treatment of secondary hemophagocytic lymphohistiocytosis

  2023cites this paper
• Immune Effector Cell-Associated HLH-like Syndrome: A Review of the Literature of an Increasingly Recognized Entity

  2023cites this paper
• The druggable transcription factor Fli-1 regulates T cell immunity and tolerance in graft-versus-host disease

  2022cites this paper
• Hemophagocytic lymphohistiocytosis in HIV-associated lymphoproliferative disorders

  2022cites this paper
• L-DEP regimen is effective as an initial therapy for adult EBV-HLH

  2022cites this paper
• Lymphoma-associated hemophagocytic syndrome: a retrospective study from a single center

  2022influential citation
• Combined IFNγ and JAK inhibition to treat hemophagocytic lymphohistiocytosis in mice.

  2022cites this paper
• sCD25 as an independent adverse prognostic factor in adult patients with HLH: results of a multicenter retrospective study

  2022cites this paper
• Case report: Ruxolitinib as first-line therapy for secondary hemophagocytic lymphohistiocytosis in patients with AIDS

  2022cites this paper
• Advances of podophyllotoxin and its derivatives: patterns and mechanisms.

  2022cites this paper
• Acute circulatory failure in critically ill patients with hemophagocytic syndrome.

  2022cites this paper
• Etoposide-containing regimens for the treatment of critically ill patients with hematological malignancy-related hemophagocytic lymphohistiocytosis

  2022cites this paper
• Dramatic Recovery after Etoposide Phosphate Infusion for Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome following Treatment with Tisagenlecleucel in a Young Patient with Relapsed Acute Lymphoblastic Leukemia: A Case Report

  2022cites this paper
• Short-term, low-dose etoposide in refractory adult-onset Still’s disease-associated macrophage activation syndrome

  2022cites this paper
• Higher efficacy of oral etoposide for mobilization of peripheral blood stem cells in patients with multiple myeloma

  2022cites this paper
• Renal involvement as a unique manifestation of hemophagocytic syndrome

  2022cites this paper
• Rare complications of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis: Time to nip them in the bud

  2022cites this paper
• Integrated omics approaches to predict T-LBL relapse risk.

  2021cites this paper
• Targeting Wee1 kinase as a therapeutic approach in Hematological Malignancies.

  2021cites this paper
• HLH or sepsis: the truth is in the T cells.

  2021cites this paper
• Histiocytic disorders

  2021cites this paper
• Clinical features, diagnosis and therapy of familial haemophagocytic lymphohistiocytosis

  2021cites this paper
• Therapeutic administration of etoposide coincides with reduced systemic HMGB1 levels in macrophage activation syndrome

  2021cites this paper
• Combinatory Delivery of Etoposide and siCD47 in a Lipid Polymer Hybrid Delays Lung Tumor Growth in an Experimental Melanoma Lung Metastatic Model

  2021cites this paper
• Short-term, Low-Dose Etoposide in Refractory Adult-Onset Still’s Disease-Associated Macrophage Activation Syndrome, a Case Series Study

  2021cites this paper
• Signaling pathways in the regulation of cytokine release syndrome in human diseases and intervention therapy

  2021cites this paper
• Case Report: Rapid Recognition and Immune Modulation of Secondary HLH Due to Disseminated HSV Infection

  2021cites this paper
• JAK inhibition for murine HLH requires complete blockade of IFNg signaling and is limited by toxicity of JAK2 inhibition.

  2021cites this paper
• Hemophagocytic Lympho-Histiocytosis HLH Triggered by Acute Hepatitis A Virus Infection: Lessons for COVID-19

  2021influential citation
• Dengue-Induced Hemophagocytic Lymphohistiocytosis: A Case Report and Literature Review

  2021cites this paper
• Haemophagocytic lymphohistiocytosis in pregnancy

  2021cites this paper
• Narrative review of chronic active EBV infection—advances in clinical management

  2021influential citation
• Characteristics and management of patients with hemophagocytic lymphohistiocytosis masquerading as liver failure

  2021cites this paper
• Management of hemophagocytic lymphohistiocytosis (HLH) associated with chimeric antigen receptor T-cell (CAR-T) therapy using anti-cytokine therapy: an illustrative case and review of the literature

  2021cites this paper
• IFN-γ Signature in the Plasma Proteome Distinguishes Pediatric Hemophagocytic Lymphohistiocytosis from Sepsis and SIRS.

  2021cites this paper
• Efficacy of Moderately Dosed Etoposide in Macrophage Activation Syndrome–Hemophagocytic Lymphohistiocytosis

  2021cites this paper
• Etoposide as an Effective Drug for Adult Macrophage Activation Syndrome: A Retrospective Study

  2021cites this paper
• Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline

  2021cites this paper
• Acute kidney injury due to cytokine storm in patients with COVID-19 infection

  2020cites this paper
• Etoposide as Salvage Therapy for Cytokine Storm Due to COVID-19.

  2020cites this paper
• Hemophagocytic lymphohistiocytosis and miliary tuberculosis in a previously healthy individual: a case report

  2020cites this paper
• Cytokine Profile Changes During the Initial Stage of Treatment for Childhood Epstein-Barr Virus-Associated Hemophagocytic Lymphohistiocytosis.

  2020cites this paper
• 淋巴瘤相关噬血细胞综合征研究进展

  2020cites this paper
• [Research progress of lymphoma associated hemophagocytic syndrome].

  2020cites this paper